Schrodinger Sees FY Drug Discovery Revenue At $65M-$75M
Schrodinger (NASDAQ:SDGR) Sees Drug discovery revenue is expected to range from $65 million to $75 million.
Read original at benzingaStocks · News reference
Schrödinger Rolls Out Early Access Version Of Bunsen
Schrödinger, Inc. (Nasdaq: SDGR) today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop computational
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 27, 2026, 11:35 AM
- Checked
- Jul 27, 2026, 11:35 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading